U.S. markets closed

10x Genomics, Inc. (TXG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
150.67+9.83 (+6.98%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close140.84
Open141.88
Bid146.08 x 900
Ask154.84 x 800
Day's Range141.88 - 150.80
52 Week Range48.78 - 166.31
Volume764,609
Avg. Volume805,387
Market Cap16.213B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.41
Earnings DateFeb 16, 2021 - Feb 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est148.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

    10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

  • 10x Genomics Reports Third Quarter 2020 Financial Results
    GlobeNewswire

    10x Genomics Reports Third Quarter 2020 Financial Results

    PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights * Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second quarter of 2020 * Completed the acquisitions of ReadCoor and CartaNA, advancing 10x Genomics into In Situ analysis with comprehensive and foundational intellectual property, key technology advances and deep talent and expertise in the emerging field * Completed a follow-on public offering of 4,600,000 shares of common stock resulting in approximately $482.2 million in net proceeds "Our strong performance this quarter demonstrates our ability to execute across all facets of the business," said Serge Saxonov, Co-Founder and CEO of 10x Genomics. "We remain focused on the frontiers of scientific discovery and we will continue to invest in the vast opportunities that lie before us, both now and well into the future."Third Quarter 2020 Financial ResultsRevenue was $71.8 million for the three months ended September 30, 2020, a 17% increase from $61.2 million for the three months ended September 30, 2019. This increase was primarily the result of increased consumables revenue driven by growth in the instrument installed base, partially offset by decreased demand due to ongoing lab closures resulting from COVID-19.Gross margin was 80% for the third quarter of 2020, as compared to 75% for the corresponding prior year period. The increase in gross margin was driven primarily by lower accrued royalties related to ongoing litigation.Operating expenses were $122.7 million for the third quarter of 2020, a 124% increase from $54.8 million for the three months ended September 30, 2019, and include $40.6 million of in-process research and development expense related to intellectual property purchased in connection with the acquisition of CartaNA. Other drivers of the increase in operating expenses this quarter include increased personnel expenses, including stock-based compensation, and increased outside legal expenses.Operating loss was $65.3 million for the third quarter of 2020, as compared to $9.1 million for the corresponding prior year period. This includes $13.8 million of stock-based compensation for the third quarter of 2020, as compared to $3.9 million for the third quarter of 2019.Net loss was $65.8 million for the third quarter of 2020, as compared to a net loss of $9.6 million for the corresponding prior year period.Cash and cash equivalents were $768.8 million as of September 30, 2020, which include net proceeds of $482.2 million arising from our successfully completed follow-on public offering.Full Year 2020 Guidance As previously announced, 10x Genomics has withdrawn its annual revenue guidance for 2020 due to the evolving environment and continued uncertainties from the impact of COVID-19.Webcast and Conference Call Information10x Genomics will host a conference call to discuss the third quarter 2020 financial results, business developments and outlook after market close on Tuesday, November 10, 2020 at 2:00 PM Pacific Time / 5:00 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xGenomics.com. The webcast will be archived and available for replay at least 45 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 2,000 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 950 issued patents and patent applications.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding the potential impact of the COVID-19 outbreak on the company’s business operations, financial performance and results of operations as well as the company’s ability to meet its anticipated cash needs for the foreseeable future. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.ContactsInvestors: investors@10xgenomics.comMedia: media@10xgenomics.com10x Genomics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data)   Three Months Ended      Nine Months Ended        September 30,      September 30,       2020  2019  2020  2019  Revenue$        71,817 $        61,207 $        186,627 $        170,604  Cost of revenue (1) 14,411  15,480  39,571  44,451  Gross profit 57,406  45,727  147,056  126,153  Operating expenses:     Research and development (1) 30,143  22,209  83,670  55,208  In-process research and development 40,637  —  40,637  —  Selling, general and administrative (1) 51,549  32,614  146,352  92,078  Accrued contingent liabilities 332  —  956  1,360  Total operating expenses 122,661  54,823  271,615  148,646  Loss from operations (65,255) (9,096) (124,559) (22,493) Other income (expense):     Interest income 28  481  1,471  986  Interest expense (397) (708) (1,365) (2,087) Other expense (income), net 361  (272) 121  (413) Loss on extinguishment of debt —  —  (1,521) —  Total other expense (8) (499) (1,294) (1,514) Loss before provision for income taxes (65,263) (9,595) (125,853) (24,007) Provision for income taxes 585  8  1,305  110  Net loss$        (65,848)$        (9,603)$        (127,158)$        (24,117) Other comprehensive income:     Foreign currency translation adjustment (366) (126) (6) (123) Comprehensive loss$        (66,214)$        (9,729)$        (127,164)$        (24,240) Net loss per share, basic and diluted $(0.65) $ (0.33)  $ (1.28)  $ (1.21)  Weighted-average shares of common stock used in computing net loss per share, basic and diluted 101,341,945  29,184,218  99,058,139  19,904,184  (1) Includes stock-based compensation expense as follows:   Three Months Ended    Nine Months Ended      September 30,    September 30,   (in thousands) 2020  2019  2020  2019  Cost of revenue$        398 $        81 $        1,108 $        171  Research and development 5,467  1,650  14,398  3,448  Selling, general and administrative 7,919  2,143  18,851  4,639   Total stock-based compensation expense $13,784  $3,874  $34,357  $8,258  10x Genomics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share data)  September 30,   December 31,     2020   2019   Assets       Current assets:        Cash and cash equivalents$        768,773 $        424,166  Restricted cash 59,451  —  Accounts receivable, net 36,026  33,371  Inventory 25,118  15,270  Prepaid expenses and other current assets 11,083  8,033  Total current assets 900,451  480,840  Property and equipment, net 65,111  48,821  Restricted cash 5,474  52,327  Operating lease right-of-use assets 45,379  —  Other assets 26,129  23,935  Total assets$        1,042,544 $        605,923  Liabilities and stockholders’ equity   Current liabilities: Accrued contingent liabilities$        77,558 $        —  Accounts payable 9,490  13,028  Accrued compensation and related benefits 11,189  12,394  Accrued expenses and other current liabilities 38,583  24,448  Term loans, current portion —  9,882  Deferred revenue, current 3,775  3,297  Operating lease liabilities 4,976  —  Total current liabilities 145,571  63,049  Term loans, noncurrent portion —  19,837  Accrued contingent liabilities —  68,658  Accrued license fee, noncurrent 11,223  16,251  Deferred rent, noncurrent —  16,120  Operating lease liabilities, noncurrent 56,618  —  Other noncurrent liabilities 4,052  1,925  Total liabilities 217,464  185,840  Commitments and contingencies    Stockholders’ equity:   Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of September 30, 2020 and December 31, 2019 —  —  Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 105,599,976 shares issued and outstanding as of September 30, 2020; 1,100,000,000, shares authorized and 96,241,596 shares issued and outstanding as of December 31, 2019 2  2  Additional paid-in capital 1,214,655  682,494  Accumulated deficit (389,525) (262,367) Accumulated other comprehensive loss (52) (46) Total stockholders’ equity 825,080  420,083  Total liabilities and stockholders’ equity$1,042,544 $605,923

  • 10x Genomics to Participate in the Stifel 2020 Healthcare Conference
    GlobeNewswire

    10x Genomics to Participate in the Stifel 2020 Healthcare Conference

    PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.comAbout 10x Genomics 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 1,750 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 825 issued patents and patent applications.Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.         Contacts Investors investors@10xgenomics.comMedia media@10xgenomics.com